Xilio Therapeutics, Inc. (XLO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Rene Russo BCPS, Pharm.D. | President, CEO & Director | 875.13k | -- | 1975 |
| Mr. Christopher Frankenfield | Chief Operating Officer | 704.85k | -- | 1982 |
| Dr. Katarina Luptakova M.D. | Chief Medical Officer | 591.92k | -- | 1976 |
| Mr. Kevin M. Brennan | Senior VP of Finance & Accounting | -- | -- | 1970 |
| Dr. Uli Bialucha Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Dr. Scott Coleman Ph.D. | Chief Development Officer | -- | -- | -- |
Xilio Therapeutics, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 73
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Upcoming Events
November 7, 2024 at 2:05 PM UTC
Xilio Therapeutics, Inc. Earnings Date
Recent Events
May 2, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission